HRTX Heron Therapeutics Inc

Price (delayed)

$12.89

Market cap

$1.31B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.51

Enterprise value

$1.28B

Highlights
The debt has declined by 3.8% year-on-year
The quick ratio has contracted by 50% YoY and by 17% from the previous quarter
The equity has declined by 46% year-on-year and by 17% since the previous quarter

Key stats

What are the main financial stats of HRTX
Market
Shares outstanding
101.83M
Market cap
$1.31B
Enterprise value
$1.28B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6
Price to sales (P/S)
14.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.34
Earnings
Revenue
$83.26M
EBIT
-$230.05M
EBITDA
-$227.08M
Free cash flow
-$198.48M
Per share
EPS
-$2.51
Free cash flow per share
-$2.17
Book value per share
$2.15
Revenue per share
$0.91
TBVPS
$3.4
Balance sheet
Total assets
$310.93M
Total liabilities
$114.71M
Debt
$24.43M
Equity
$196.23M
Working capital
$171.37M
Liquidity
Debt to equity
0.12
Current ratio
2.7
Quick ratio
2.03
Net debt/EBITDA
0.16
Margins
EBITDA margin
-272.7%
Gross margin
58.2%
Net margin
-274.2%
Operating margin
-273.3%
Efficiency
Return on assets
-61.4%
Return on equity
-88.3%
Return on invested capital
-108%
Return on capital employed
-109.5%
Return on sales
-276.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HRTX stock price

How has the Heron Therapeutics stock price performed over time
Intraday
-1.15%
1 week
0.16%
1 month
-21.5%
1 year
-23.04%
YTD
-39.11%
QTD
-16.95%

Financial performance

How have Heron Therapeutics's revenue and profit performed over time
Revenue
$83.26M
Gross profit
$48.48M
Operating income
-$227.54M
Net income
-$228.31M
Gross margin
58.2%
Net margin
-274.2%
The net margin has dropped by 98% year-on-year and by 7% since the previous quarter
HRTX's operating margin has dropped by 92% year-on-year and by 6% since the previous quarter
HRTX's gross profit is down by 41% year-on-year and by 8% since the previous quarter
HRTX's revenue is down by 40% year-on-year and by 6% since the previous quarter

Growth

What is Heron Therapeutics's growth rate over time

Valuation

What is Heron Therapeutics stock price valuation
P/E
N/A
P/B
6
P/S
14.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.34
Heron Therapeutics's EPS has decreased by 11% YoY
The equity has declined by 46% year-on-year and by 17% since the previous quarter
The P/B is 36% lower than the 5-year quarterly average of 9.5 and 2.1% lower than the last 4 quarters average of 6.2
HRTX's price to sales (P/S) is 73% less than its 5-year quarterly average of 53.8 and 9% less than its last 4 quarters average of 15.8
HRTX's revenue is down by 40% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Heron Therapeutics business performance
Heron Therapeutics's return on sales has shrunk by 94% YoY and by 7% QoQ
The ROIC has plunged by 63% YoY and by 16% from the previous quarter
Heron Therapeutics's ROE has plunged by 55% YoY and by 17% from the previous quarter
HRTX's ROA is down by 43% YoY and by 12% QoQ

Dividends

What is HRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HRTX.

Financial health

How did Heron Therapeutics financials performed over time
Heron Therapeutics's total assets is 171% higher than its total liabilities
The quick ratio has contracted by 50% YoY and by 17% from the previous quarter
The current ratio has contracted by 40% YoY and by 12% from the previous quarter
The debt is 88% smaller than the equity
The debt to equity has soared by 71% year-on-year and by 20% since the previous quarter
The equity has declined by 46% year-on-year and by 17% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.